Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Clinical Trial ID NCT00401414

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.	N Engl J Med	2005	8.77
2	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.	Lancet	1999	7.39
3	Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.	JAMA	2002	5.26
4	Clinical importance of the cytochromes P450.	Lancet	2002	3.77
5	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.	Thromb Haemost	2005	2.25
6	Flexible induction dose regimen for warfarin and prediction of maintenance dose.	Br Med J (Clin Res Ed)	1984	1.83
7	Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.	J Gen Intern Med	2009	1.77
8	Warfarin dosing and cytochrome P450 2C9 polymorphisms.	Thromb Haemost	2004	1.12
9	Major bleeding complications in a specialized anticoagulation service.	Am J Cardiol	2005	1.03
10	The Creating an Optimal Warfarin Nomogram (CROWN) Study.	Thromb Haemost	2011	0.82
11	Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people.	Age Ageing	1998	0.81
12	Effectiveness and safety of long-term anticoagulation of patients >/=90 years of age with atrial fibrillation.	Am J Cardiol	2002	0.76